U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when ...

Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), the first and only subcutaneously (SC) ...

Predicting the 2025 College Football Playoff and how Ohio State football finishes the season: Buckeye Talk podcast

COLUMBUS, Ohio -- Welcome to the Buckeye Talk Live Show. A weekly podcast brought to you live at noon every Wednesday for the 2025 season as Ohio State hopes to repeat as national champions. Every ...